Breast Biopsy Devices: Empowering Early Detection and Treatment

 The major factors driving the growth of Breast Biopsy Devices Market include the growing prevalent cases of breast cancer, the increasing number of breast cancer screening programs, the growing demand for minimally invasive and non-invasive procedures, and the improved reimbursement scenario.

What the Market Looks Like?

Breast Biopsy Devices Market  is projected to reach USD 2.6 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 10.0% from 2023 to 2028.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189011805

Market Segmentation: -

Based on the type, the global breast biopsy devices market is segmented into biopsy needles, guidance systems, localization wires, assay kits, liquid biopsy instruments, biopsy tables, and other devices. The assay kits segment is expected to grow at the highest CAGR during the forecast period.

Based on the procedure, the breast biopsy devices market is segmented into needle open surgical breast biopsy, breast biopsy, and liquid breast. The liquid breast biopsy segment is anticipated to register the highest growth rate over the forecast period.

Based on application, the market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening accounted for the largest share of the market in 2022. However, the therapy selection segment is expected to grow at the highest CAGR during the forecast period.

Based on the end user, the breast biopsy devices market is segmented into hospitals & surgical centers, breast care centers, and imaging clinics & diagnostic centers. The hospitals & surgical centers segment accounts for the largest share of the market in 2022.

What Drives the Market?

The growth of the global market for Breast Biopsy is primarily influenced by the following factors:

1 Growing incidence of breast cancer
2 Increasing number of breast cancer screening programs
3 Increasing demand for minimally invasive and non-invasive procedures
4 Growing awareness regarding early detection of breast cancer
5 Improved reimbursement scenario.

Regional Analysis: -

The North American breast biopsy devices market is estimated to grow significantly from 2023 to 2028. factors such as ongoing technological advancements, rising breast cancer incidence rates, favorable reimbursement scenarios, and new breast density notification laws drive market growth in North America. This region has a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players.

Get Data as per your Format and Definition | REQUEST FOR CUSTOMIZATION: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=189011805

Recent Developments:

• Hologic, Inc, an innovative medical technology company primarily focused on improving women’s health, announced today that it has completed the purchase of SOMATEX Medical Technologies GmbH; the deal size is $64 million.
• In 2022 Danaher Corporation launched Mammotome Revolve EX Dual Vacuum-Assisted Breast Biopsy System, the first vacuum-assisted biopsy device designed specifically for the excision of benign breast lesions and is twice as fast as traditional vacuum-assisted breast biopsy systems.
• Argon Medical Devices announced the launch of the SuperCore advantage semi-automatic biopsy instrument’s newest addition to its soft tissue biopsy product portfolio in the united states. The next-generation soft tissue biopsy instrument provides a superior volume of tissue samples. Collecting more tissue volume may increase the likelihood of an accurate diagnosis.

Top Key Players: -

As of 2022, prominent players in the breast biopsy devices market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Medtronic (IRL), Merit Medical Systems (US), Menarini-Silicon Biosystems (ITL),  Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany) and Exact Sciences Corporation (US).

The breast biopsy devices market is highly competitive, with several key players globally. Market dynamics, such as technological advancements, regulatory changes, and the evolving healthcare landscape, can impact the growth and development of this market.

Revolutionizing Diagnostics: The Rise of Isothermal Nucleic Acid Amplification Technology

 The growth of the market is attributed the growing funding initiatives for molecular diagnostics & infectious diseases, and recent launches of INAAT consumables by prominent market players. However, the unfavorable reimbursement scenario for in vitro diagnostic tests is a major factor restraining market growth. The isothermal nucleic acid amplification technology market is expected to grow at a CAGR of 9.2% during the forecast period.

 

The report Isothermal Nucleic Acid Amplification Technology Market  is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2023, at a CAGR of 9.2% during the forecast period.

KEY MARKET DYNAMICS

           1 DRIVERS

                    1 Recent launches of INAAT consumables by prominent market players

                    2 Growing funding initiatives for molecular diagnostics & infectious disease diagnostics

                    3 High prevalence of infectious diseases

           2 RESTRAINTS

                    1 Unfavorable reimbursement scenario for in vitro diagnostic tests

           3 OPPORTUNITIES

                    1 INAAT tests as point-of-care tools

                    2 Start-ups focusing on INAAT

           4 CHALLENGES

                    1 Dominance of PCR

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=839

Market Segmentation

·         Based on the product, the INAAT market is segmented into assay, kits, and reagents, and systems. The assay, kits, and reagents segment accounted for the largest share in 2022.

·         Based on technology, the isothermal nucleic acid amplification technology market is segmented into loop-mediated isothermal amplification (LAMP), transcription-mediated amplification (TMA), strand displacement amplification (SDA), nicking enzyme amplification reaction (NEAR), single-primer isothermal amplification (SPIA), and other technologies.

·         Based on application, the INAAT market is segmented into infectious disease diagnosis, blood screening, and other applications. The disease diagnosis segment is expected to dominate the market in 2022.

·         Based on the end user, the market is divided into hospitals, reference laboratories, academic and research institutes, and other end users. The hospital segment is expected to account for the largest share of the INAAT market in 2022.

Regional Analysis

North America is expected to account for the largest share of the global INAAT market, followed by Europe in 2022. The largest share of the North American market is attributed to the presence of a leading market players, growing burden of infectious diseases and availability of R&D funding for molecular diagnostics.

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=839

Recent Developments

·         In May 2022, Hologic, Inc. (US) received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system.

·         In December 2021, Hologic, Inc. (US) launched Panther Trax, which offers full automation to meet high-volume testing demands and will be commercially available in the US, Europe, Canada, Australia, and New Zealand.

·         In September 2020, Abbott (US) received approval from Health Canada for the ID NOW rapid COVID-19 testing device for use in Canada.

Top Key Players

The prominent players operating in INAAT market are Grifols, S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), Eiken Chemical Co., Ltd. (Japan), bioMérieux SA (France), Tecan Trading AG (Switzerland), New England Biolabs (US), QIAGEN N.V. (Germany), DiaSorin S.p.A. (Italy), General Electric (US), OptiGene Limited (UK), Quidel Corporation (US), Thermo Fisher Scientific (US), Genomtec (Poland), Mast Group Ltd. (UK), Ustar Biotechnologies (China), Jena Bioscience GmbH (Germany), Atila BioSystems (US), TwistDx Limited (UK), LGC Limited (UK), Life Sciences Advanced Technologies (US), GenoSensor Corporation (US), and PCR Biosystems (UK).

Factors influencing the regional dynamics of the INAAT market include healthcare infrastructure, research funding, disease prevalence, regulatory environment, and the presence of key market players. the market was poised for growth globally, with increasing applications in infectious disease diagnostics, point-of-care testing, and environmental monitoring.

 

Rapid Growth Projected: Amniotic Products Market worth $1,289 million by 2028

 The growth of the Amniotic Products market is majorly driven by rising awareness programs for wound care treatment and management and venture capital investments and government funding. However, competition from alternative therapies may challenge the growth of this market.

The report Amniotic Products Market  is projected to reach USD 1,289 million by 2028 from USD 900 million in 2023, at a CAGR of 7.4% during the forecast period.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191575976

Market Segmentation: -

The Europe amniotic products market is segmented into Germany, France, the UK, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period. The major factors contributing to the growth of this market are the high prevalence of diabetes and venous ulcers in the UK, increasing R&D activities, strategic developments by key players, and the growing geriatric population.

Based on the end user, the amniotic products market is segmented into Hospitals, & Ambulatory Surgical Centers, and Other End Users. The Hospitals, & Ambulatory Surgical Centers registered the highest CAGR, increasing hospital admissions due to chronic wounds (such as pressure and diabetic foot & venous leg ulcers) and the rising incidence of hospital-acquired pressure ulcers are key drivers for the growth of this end-user segment.

Regional Analysis:

The APAC amniotic products market is segmented into Japan, China, and Rest of Apac. In 2022, China accounted for the largest share of the Asian amniotic products market. The large share of China can be attributed to the economic growth in the country, rising incidence of diabetes, significantly high cases of road accidents, increasing disposable income of the middle-class population, growth in the geriatric population, and favourable government support.

Recent Developments of Amniotic Products Industry

• In 2021, The company VIVEX Biologics (US) launched Cygnus Matrix Disks with the latest configuration of the Cygnus family of amniotic tissue allografts.
• In 2021, MiMedx (US) received approval from the Japanese Ministry of Health, Labour, and Welfare for the commercialization of EPIFIX in Japan.
• In 2021, The company Celularity Inc. (US) entered into an exclusive distribution agreement for the commercial distribution rights for orthopedic surgery and sports medicine products with Arthrex, Inc. (US).

Inquiry Before Buying: -https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=191575976

Top Key Players:

The significant players in the amniotic products market are mimedx (US), Smith+Nephew (UK), Organogenesis Inc. (US), Integra LifeSciences (US), Stryker (US), APPLIED BIOLOGICS. (US), Celularity Inc. (US), Corza Ophthalmology (US), Lucina BioSciences (US), and Next Biosciences. (South Africa).

Conclusion:

The Amniotic Products Industry is poised for substantial growth, driven by increasing awareness, investments, and the need for innovative solutions in wound care and regenerative medicine. As we move forward, it will be exciting to witness how this industry continues to evolve and contribute to improving patient outcomes worldwide.

 

Unveiling the Future: Exploring the Digital X-ray Market

 As per the recently published report by MarketsandMarkets™, The report " Digital X-ray Market by Portability (Fixed, Portable), Applications (General, Dental, Mammography, Cancer, Fluoroscopy), Technology (Direct, Computed), System (Retrofit, New), End Users, Price Range, Type, and Region - Global Forecast to 2026", The global digital X-ray market is expected to reach USD 16.4 billion by 2026 from an estimated USD 11.1 billion in 2021, at a CAGR of 8.1% from 2021 to 2026.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1164
 
Browse

• 230     Market Data Tables
• 45       Figures
• 280     Pages and in-depth TOC on "Digital X-ray Market - Global Forecast to 2026”

Some of the prominent key players are:

• Siemens Healthineers (Germany),
• GE Healthcare (US),
• Koninklijke Philips N.V. (Netherlands),
• FUJIFILM Holdings Corporation (Japan),
• Canon, Inc. (Japan), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Digital X-ray Market.

• Based on technology, the digital X-ray market is segmented into direct radiography and computed radiography. The direct radiography segment commanded the largest share of the global digital X-ray market in 2020.
• Based on portability, the digital X-ray market is segmented into fixed digital X-ray systems and portable digital X-ray systems. Fixed digital X-ray systems include floor-to-ceiling-mounted systems and ceiling-mounted systems, while portable digital X-ray systems include mobile X-ray systems and handheld X-ray systems.
• The global digital X-ray systems market is divided into new and retrofit digital X-ray systems. The retrofit digital X-ray systems segment is expected to dominate the market during the forecast period.
• Based on applications, the digital X-ray market is segmented into general radiography, dental applications, fluoroscopy, cancer, and mammography applications. The general radiography segment is expected to dominate this market during the forecast period.
• The digital X-ray market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for digital X-ray systems, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The major factors driving the growth of this market include the increasing geriatric population and growth in disease incidence as well as favorable government regulations, investments, and initiatives. The advantages of digital X-ray systems have played a key part in their adoption; their speed and accuracy, as well as quick processing times, allow for significantly higher patient screening volumes than earlier. This has pushed companies to focus on product development and innovation. However, these systems are priced at a premium, which slows their greater adoption. Other factors such as declining reimbursements, lack of infrastructure, particularly in developing and underdeveloped countries, and potential risks associated with radiation exposure are also expected to hinder the growth of this market.

 

Bioimpedance Analyzers Market: Increasing prevalence of lifestyle diseases

 As per the recently published report by MarketsandMarkets™, The report "Bioimpedance Analyzers Market by Type (Single, Multi & Dual Frequency), Modality (Wired, Wireless), Application (Segmental Body Measurement, Whole Body Measurement), End User (Fitness Clubs, Home Users, Hospitals), & Region- Global Forecast to 2028", is projected to reach USD 927 million by 2028 from USD 564 million in 2023, at a CAGR of 10.4% during the forecast period. 

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144536297
 
Browse

• 126   Market Data Tables
• 32     Figures
• 170   Pages and in-depth TOC on " Bioimpedance Analyzers Market - Global Forecast to 2028”

Some of the prominent key players are:

• OMRON Corporation (Japan),
• Tanita Corporation (Japan),
• InBody (South Korea),
• RJL Systems (US), 
• seca GmbH & Co. KG (Germany), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Bioimpedance Analyzers Market.

• The bioimpedance analyzers market, by product, has been segmented into multi-frequency, single-frequency, and dual-frequency bioimpedance analyzers. In 2022, the multi-frequency bioimpedance analyzers segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period.
• By usage type, the global bioimpedance analyzers market is broadly segmented into into consumer-grade and professional-grade bioimpedance analyzers. The professional grade bioimpedance analyzers segment accounted for the largest share of the market in 2022.
• Based on application, the bioimpedance analyzers market is segmented into segmental body measurement and whole-body measurement. The segmental body measurement segment accounted for the largest share of the market in 2022. Also, this segment is estimated to witness the highest growth during the forecast period.
• Based on the region, the bioimpedance analyzers market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America market is driven by rising adoption of bioimpedance analyzers by atheletes to track progress and fitness initiatives by government and local groups.

Get Free Sample Pages: 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=144536297

The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals and fitness clubs, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.

Genetic Wellness: Insights into the Growing Preimplantation Genetic Testing Market

As per the recently published report by MarketsandMarket™, The report  "Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028", is projected to reach USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 11.4% during the forecast period. 

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
 
Browse

• 182     Market Data Tables
• 44       Figures
• 245     Pages and in-depth TOC on "Preimplantation Genetic Testing Market - Global Forecast to 2028”

Some of the prominent key players are:

• Illumina, Inc. (US),
• Thermo Fisher Scientific Inc. (US),
• Agilent Technologies, Inc. (US),
• Revvity (US), 
• The Cooper Companies, Inc. (US), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Preimplantation Genetic Testing Market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=605

• Preimplantation genetic screening, or aneuploidy screening, involves screening embryos for the assessment of aneuploidy. This segment is expected to dominate the global preimplantation genetic testing market during the forecast period, driven by a decrease in female fertility with rising maternal age, better implantation rate and reduced IVF cycle times.
• Based on the products, the global preimplantation genetic testing market is broadly segmented into instruments, reagents & consumables, and software & services. The expanding applications of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders).
• By end user, the global preimplantation genetic testing market is broadly segmented into hospitals, diagnostic labs, fertility clinics, and other end users. The large share of this segment can be attributed to factors such as the increasing number of fertility centers globally, the high success rate of treatment in fertility centers, and growing medical tourism in developing countries.
• Based on the region, the preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American market is driven by high incidence of chromosomal disorders, and an increasing number of awareness programs.

The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth in this market is attributed to the increasing demand for assisted reproductive technologies, rising maternal age trends, and ongoing research and development in the field of genetics. On the other hand, socio-ethical concerns surrounding preimplantation genetic testing may challenge the growth of market. Whereas, use of fertility treatment options by single parents and same-sex couples provides growth opportunities for market.

Infusion Pump Market Trends: Innovations Shaping the Future of Medical Treatment

 The growing number of surgeries performed, and rising prevalence of chronic diseases are some factors that provide key opportunities for key players in the market. However, product recalls by some major players, and stringent regulations on manufacture of infusion pumps are expected to challenge/restrain the growth of the market.

The report Infusion Pump Market size is 17.1 billion for 2023 and is projected to reach USD 26.2 billion by 2029, at a CAGR of 7.3% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=90374506

KEY MARKET DYNAMICS

           1 MARKET DRIVERS

                    1 Rising demand for ambulatory infusion pumps in home care settings

                    2 Increasing incidence of chronic diseases along with rapid growth in geriatric population

                    3 Growing number of surgical procedures performed     

           2 MARKET RESTRAINTS

                    1 Product recalls

                    2 Stringent regulatory requirements for new products

                    3 Increasing adoption of refurbished and rental infusion pumps

           3 MARKET OPPORTUNITIES

                    1 High growth opportunities in emerging countries

                    2 Growing adoption of specialty infusion systems

           4 MARKET CHALLENGES

                    1 Increasing incidence of medication errors and lack of wireless connectivity in most hospitals              

Market Segmentation:

In 2022, the market for dedicated accessories and consumables accounted for the largest share and was also the faster growing segment of the infusion pump accessories and consumables market. This segment is mainly driven by the requirement of compatible administration sets designed for a particular type of infusion pump by the manufacturer to ensure optimum results of dedicated accessories.

Out of the dedicated accessories and consumables market in 2022, the volumetric infusion pump accessories and consumables segment accounted for the largest share. High adoption of volumetric infusion pumps and related accessories in hospitals for the purpose of delivering large volumes of medications and nutrients to patients is pushing the market forward.

Regional Analysis

The infusion pump market is segmented into five major regions, namely, Europe, North America, Latin America, the Middle East and Africa, and Asia Pacific (APAC). Asia Pacific attributes to the highest growth rate amongst the other regions during the forecast period. The rapid infrastructure growth, increase in disposable incomes, and increase incidences of chronic diseases are factors which are likely to support the growth of infusion pump market in the region. The emerging Asian countries, such as China, and India, offer significant growth opportunities for market players.

Recent Developments of the Infusion Industry

• In August 2023, ICU Medical, Inc. (US) received FDA clearance for its Plum Duo infusion pump, which will make it available for customers in the US in early 2024.
• In April 2023, Fresenius Kabi (Germany) announced that its Ivenix Infusion System has received an Innovative Technology contract from Vizient, Inc. (US), which sets terms for hospitals to evaluate and purchase the Ivenix Infusion System.
• In August 2022, Becton Dickinson and Company (US)’s Novum IQ Syringe Infusion Pump received FDA approval.
• In March 2022, Freseniu kabi (Germany) received US FDA approval for the wireless Agilia Connect Infusion System, which includes the Agilia Volumetric Pump and the Agilia Syringe Pump with Vigilant Software Suite-Vigilant Master Med technology.
• In January 2022, ICU Medical, inc. (US) acquired Smiths Medical, inc. (US) to increase its share in the infusion pump market by adding syringe and ambulatory pumps to its portfolio.

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=90374506

Top Key Players:

The key players in the infusion pump market Becton, Dickinson and Company (US), Baxter International, Inc. (US), and B. Braun Melsungen AG (Germany). These companies adopted strategies such as product launches, collaborations, partnerships, and acquisitions to strengthen their presence in the market.

 

Patient Registry Software Market Share, Size, Trends and Global Forecast

 The use of cloud-based patient registry solutions helps deliver insights from a multi-terabyte database anywhere, anytime, and on any platform, with ease. In addition, these solutions do not require any upfront capital investment for hardware and provide faster data transfer between organizations. Considering these advantages, the preference for cloud-based patient registry solutions is expected to increase among end users during the forecast period.

The global Patient registry software market is projected to reach USD 2.8 billion by 2026 from USD 1.4 billion in 2021, at a CAGR of 15.0% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144694594  

Key Market Dynamics

1.DRIVERS
                   1.1 Government initiatives to build patient registries
                   1.2 Rising pressure to improve quality of care and reduce healthcare costs
                   1.3 Rising adoption of EHRs and other eHealth solutions
                   1.4 Growing patient volume due to global outbreak of COVID-19
                   1.5 Growing use of patient registry data for post-marketing surveillance

2. RESTRAINTS
                   2.1 Privacy- and data security-related concerns
                   2.2 Shortage of trained and skilled resources

3. OPPORTUNITIES
                   3.1 Rising number of accountable care organizations
                   3.2 Emergence of cloud-based patient registry solutions
                   3.3 High adoption rate of subscription model

4. CHALLENGES
                   4.1 Lack of interoperability and integration
                   4.2 Reluctance to adopt advanced solutions
                   4.3 Lack of awareness.

Market Segmentation:

On the basis of type of registry, the disease registries segment accounted for the largest share of the patient registry software market in 2020. The large share of this segment can be attributed to the increase in the aging population, rising prevalence of chronic and rare & new diseases, growing awareness on the role of registries in health management, and the adoption of EHRs across the globe.

Based on end user, the hospitals & medical practices segment is expected to register the highest CAGR during the forecast period. Factors responsible for the growth of this segment are growing prevalence of research, QM and improvement, facility planning and marketing, and monitoring patient outcomes.

Regional Analysis:

Growth of the patient registry software market in the Asia Pacific region is mainly driven by the increasing incidence of chronic diseases, rising awareness about the benefits of EHRs, improvements in healthcare systems, the development of medical tourism in Asian countries, and high demand for EHRs in Asian countries. The adoption of innovative technologies is increasing in Asia Pacific. In this region, disease registries are a prime focus area, while medical devices and other product registries are comparatively underdeveloped. The region shows a very high demand for EHRs due to its rising geriatric population and prevalence of chronic conditions.

Inquiry Before Buying : https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=144694594

Recent Developments of Patient Registry Software Industry

·         In March 2021, ESO Solutions (US) entered into a partnership with Virginia EMS Systems (US) to deliver a statewide EMS data repository and statewide trauma registry for the collection and analysis of data to reveal key insights and trends.

·         In December 2020, ImageTrend, Inc. (US) announced the latest National Trauma Data Bank (NTDB) Data Dictionary will be available in Patient Registry on January 1, 2021.

·         In November 2020, ArborMetrix, Inc. (US) entered into a partnership with the American Academy of Pediatrics to develop and grow a clinical registry to advance all children's health, well-being, and development.

Top Key Players:

Some of the prominent players in this patient registry software market are IBM Corporation (US), IQVIA Holdings (US), OpenText Corporation (Canada), Optum (US), Premier, Inc. (US), ArborMetrix, Inc. (US), FIGmd (US), McKesson Corporation (US), Syneos Health (US), Dacima Software, Inc. (Canada), ifa Systems AG (Germany), Medstreaming- M2S (US), ImageTrend, Inc. (US), Evado Clinical (Australia), WIRB Copernicus Group (US), Global Vision Technologies, Inc. (India), Conduent, Inc. (US), Elekta AB (Sweden), Cedaron (US), LUMEDX (US), Armus Corp (US), Phamax AG (Switzerland), and Versaform Systems Corp (US), ESO Solutions (US) and Ordinal Data, Inc. (US).

In conclusion, the emergence of cloud-based patient registry solutions has revolutionized how healthcare organizations manage patient data and conduct medical research. The benefits of scalability, cost-efficiency, accessibility, security, and data analytics make cloud-based solutions an attractive option for organizations aiming to streamline their patient registry operations and accelerate research efforts. However, careful consideration of data privacy, migration strategies, provider reliability, and customization needs is essential when adopting such solutions.